Nothing Special   »   [go: up one dir, main page]

SG11201701704XA - Compositions and methods for treating proliferation disorders - Google Patents

Compositions and methods for treating proliferation disorders

Info

Publication number
SG11201701704XA
SG11201701704XA SG11201701704XA SG11201701704XA SG11201701704XA SG 11201701704X A SG11201701704X A SG 11201701704XA SG 11201701704X A SG11201701704X A SG 11201701704XA SG 11201701704X A SG11201701704X A SG 11201701704XA SG 11201701704X A SG11201701704X A SG 11201701704XA
Authority
SG
Singapore
Prior art keywords
compositions
methods
proliferation disorders
treating proliferation
treating
Prior art date
Application number
SG11201701704XA
Inventor
Daniel T Dransfield
Sudharshan Eathiraj
Jean-Marc Lapierre
Brian Schwartz
Yi Yu
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of SG11201701704XA publication Critical patent/SG11201701704XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
SG11201701704XA 2014-09-05 2015-09-04 Compositions and methods for treating proliferation disorders SG11201701704XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046502P 2014-09-05 2014-09-05
US201462082236P 2014-11-20 2014-11-20
PCT/US2015/048520 WO2016037044A1 (en) 2014-09-05 2015-09-04 Compositions and methods for treating proliferation disorders

Publications (1)

Publication Number Publication Date
SG11201701704XA true SG11201701704XA (en) 2017-04-27

Family

ID=55436479

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701704XA SG11201701704XA (en) 2014-09-05 2015-09-04 Compositions and methods for treating proliferation disorders

Country Status (14)

Country Link
US (1) US9949981B2 (en)
EP (1) EP3189036B1 (en)
JP (2) JP6574245B2 (en)
KR (1) KR20170045748A (en)
CN (2) CN107074769B (en)
AU (2) AU2015311751B2 (en)
BR (1) BR112017004459A2 (en)
CA (1) CA2958770A1 (en)
ES (1) ES2955926T3 (en)
IL (2) IL250715B (en)
MX (1) MX2017002892A (en)
RU (2) RU2711500C2 (en)
SG (1) SG11201701704XA (en)
WO (1) WO2016037044A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180042356A (en) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 How to treat cancer
WO2017160698A1 (en) * 2016-03-14 2017-09-21 Pierce Biotechnology Inc. DETECTION AND QUANTIFICATION OF AKT-mTOR PATHWAY PROTEINS
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
AU2018217139A1 (en) * 2017-02-02 2019-08-22 Epizyme, Inc. Cancer treatment modalities
WO2019071171A1 (en) * 2017-10-05 2019-04-11 The Board Of Trustees Of The University Of Illinois Method of treating sickle cell disease
CN110669015A (en) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 Preparation method of FGFR inhibitor
WO2020102804A2 (en) * 2018-11-16 2020-05-22 Arqule, Inc. Pharmaceutical combination for treatment of cancer
WO2020181009A1 (en) * 2019-03-04 2020-09-10 Northwestern University Bacterial enzymatic conversion of anthracyclie chemotherapeutics
WO2022053708A1 (en) * 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma
TW202214631A (en) * 2020-09-30 2022-04-16 中國商正大天晴藥業集團股份有限公司 Compound as Akt kinase inhibitor
CN112225745B (en) * 2020-11-16 2021-10-12 烟台大学 Isopilasin compound with anti-tumor activity, preparation method and application
WO2023168291A1 (en) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2379506T3 (en) * 2008-12-30 2015-12-14 Arqule Inc Substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine compounds
US8273754B2 (en) * 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
US8049005B2 (en) * 2009-03-31 2011-11-01 Arqule, Inc. Substituted tetrahydropyrazolo-pyrido-azepine compounds
EP2519522B1 (en) * 2009-12-30 2014-09-24 ArQule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
AU2012272937B2 (en) 2011-06-24 2016-09-29 Arqule, Inc Substituted imidazopyridinyl-aminopyridine compounds

Also Published As

Publication number Publication date
MX2017002892A (en) 2017-06-06
US20160067260A1 (en) 2016-03-10
ES2955926T3 (en) 2023-12-11
US9949981B2 (en) 2018-04-24
IL277028A (en) 2020-10-29
CN111494378A (en) 2020-08-07
JP6837525B2 (en) 2021-03-03
AU2015311751B2 (en) 2020-03-12
RU2017111204A3 (en) 2019-03-25
IL250715A0 (en) 2017-04-30
RU2711500C2 (en) 2020-01-17
RU2017111204A (en) 2018-10-05
EP3189036A4 (en) 2018-04-04
JP2020002148A (en) 2020-01-09
AU2015311751A1 (en) 2017-03-09
AU2020203706B2 (en) 2022-01-13
KR20170045748A (en) 2017-04-27
CN107074769B (en) 2020-04-07
RU2019142694A (en) 2020-02-26
EP3189036A1 (en) 2017-07-12
WO2016037044A1 (en) 2016-03-10
JP6574245B2 (en) 2019-09-11
IL250715B (en) 2020-09-30
CN107074769A (en) 2017-08-18
CA2958770A1 (en) 2016-03-10
AU2020203706A1 (en) 2020-06-25
BR112017004459A2 (en) 2017-12-05
EP3189036B1 (en) 2023-07-19
JP2017526698A (en) 2017-09-14

Similar Documents

Publication Publication Date Title
IL251721A0 (en) Compositions and methods for treating cns disorders
HK1243640A1 (en) Methods and compositions for treating ulcers
RS60642B1 (en) Compositions and methods for treating cns disorders
PT3224269T (en) Compositions and methods for treating cns disorders
IL250715A0 (en) Compositions and methods for treating proliferation disorders
IL251759B (en) Compositions and methods for treating insomnia
PT3200815T (en) Methods and compositions for treating cancer
IL247699A0 (en) Compositions and methods for treating kidney disorders
PL3189074T3 (en) Compositions and methods for treating and preventing inflammation
IL250114A0 (en) Methods and compositions for treating hiv-related disorders
EP3262065C0 (en) Methods and compositions for treating dystroglycanopathy disorders
ZA201605109B (en) Compositions and methods for treating neutropenia
HK1246206A1 (en) Compositions and methods for treating glaucoma
HK1244782A1 (en) Compositions and methods for treating diseases and conditions
GB201521083D0 (en) Compositions for treatment and methods thereof